Lorus Therapeutics Inc – Product Pipeline Review – Q1 2011
Summary
Global Market Direct’s pharmaceuticals report, “Lorus Therapeutics Inc - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
Summary
Global Market Direct’s pharmaceuticals report, “Lorus Therapeutics Inc - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Lorus Therapeutics Inc - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Lorus Therapeutics Inc human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Lorus Therapeutics Inc with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Lorus Therapeutics Inc’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
- Evaluate Lorus Therapeutics Inc’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Lorus Therapeutics Inc in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Lorus Therapeutics Inc’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Lorus Therapeutics Inc.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Lorus Therapeutics Inc and identify potential opportunities in those areas.
Table of Content
Table of Content
List of Tables
List of Figures
Lorus Therapeutics Inc Snapshot
Lorus Therapeutics Inc Overview
Key Information
Key Facts
Lorus Therapeutics Inc – Research and Development Overview
Key Therapeutic Areas
Lorus Therapeutics Inc – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Lorus Therapeutics Inc – Pipeline Products Glance
Lorus Therapeutics Inc Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Lorus Therapeutics Inc–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Lorus Therapeutics Inc – Drug Profiles
GTI 2040 + Cytarabine
Product Description
Mechanism of Action
R&D Progress
LOR-2040
Product Description
Mechanism of Action
R&D Progress
LOR-2040 + Cytarabine
Product Description
Mechanism of Action
R&D Progress
Virulizin
Product Description
Mechanism of Action
R&D Progress
LOR-253
Product Description
Mechanism of Action
R&D Progress
IL-17E
Product Description
Mechanism of Action
R&D Progress
LOR-1284
Product Description
Mechanism of Action
R&D Progress
LOR-220
Product Description
Mechanism of Action
R&D Progress
LOR-253
Product Description
Mechanism of Action
R&D Progress
LOR-264
Product Description
Mechanism of Action
R&D Progress
LOR-500
Product Description
Mechanism of Action
R&D Progress
Lorus Therapeutics Inc – Pipeline Analysis
Lorus Therapeutics Inc – Pipeline Products by Therapeutic Class
Lorus Therapeutics Inc - Pipeline Products By Target
Lorus Therapeutics Inc – Pipeline Products by Route of Administration
Lorus Therapeutics Inc – Pipeline Products by Molecule Type
Lorus Therapeutics Inc – Recent Pipeline Updates
Lorus Therapeutics Inc - Dormant Projects
Lorus Therapeutics Inc - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Virulizin + Gemcitabine
Lorus Therapeutics Inc – Company Statement
Lorus Therapeutics Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Financial Deals Landscape
Lorus Therapeutics Inc, Deals Volume Summary, 2004 to YTD 2011
Lorus Therapeutics Inc, Deals Summary By Region, 2004 to YTD 2011
Lorus Therapeutics Inc, Deals Summary, 2004 to YTD 2011
Lorus Therapeutics Inc Detailed Deal Summary
Equity Offering
Lorus Therapeutics Completes Private Placement Of $2 Million
Lorus Therapeutics Completes Rights Offering Of $3.63 Million
Lorus Therapeutics Completes Private Placement Of $1.6 Million
Lorus Therapeutics Completes Private Placement Of $9.22 Million
Debt Offering
Lorus Therapeutics Completes Private Placement Of Convertible Debentures For $11.96 Million
Lorus Therapeutics Extends Co-Operative Research Agreement With NCI
Lorus Therapeutics Enters Into A Research Agreement With Dr. Guido Marcucci
Lorus Therapeutics Enters Into An Agreement With Sumitomo and Koken
Licensing Agreements
Lorus Therapeutics Extends Agreement With Zor Pharmaceuticals
Lorus Therapeutics Enters Into Licensing Agreement With Zor Pharmaceuticals
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Lorus Therapeutics Inc – Pipeline by Therapy Area and Indication, 2011
Lorus Therapeutics Inc – Pipeline by Stage of Development, 2011
Lorus Therapeutics Inc – Monotherapy Products in Pipeline, 2011
Lorus Therapeutics Inc – Combination Treatment Modalities in Pipeline, 2011
Lorus Therapeutics Inc - Phase II, 2011
Lorus Therapeutics Inc - Phase I, 2011
Lorus Therapeutics Inc - Pipeline By Therapeutic Class, 2011
Lorus Therapeutics Inc - Pipeline By Target, 2011
Lorus Therapeutics Inc – Pipeline By Route of Administration, 2011
Lorus Therapeutics Inc – Pipeline By Molecule Type, 2011
Lorus Therapeutics Inc – Recent Pipeline Updates, 2011
Lorus Therapeutics Inc - Dormant Developmental Projects, 2010
Lorus Therapeutics Inc - Discontinued Pipeline Products, 2010
Lorus Therapeutics Inc, Subsidiaries
Lorus Therapeutics Inc, Deals Summary, 2004 to YTD 2011
Lorus Therapeutics Inc, Deals Summary by Region, 2004 to YTD 2011
Lorus Therapeutics Inc, Deals Summary, 2004 to YTD 2011
LIST OF FIGURES
Lorus Therapeutics Inc – Pipeline by Therapy Area and Indication, 2011
Lorus Therapeutics Inc – Pipeline by Stage of Development, 2011
Lorus Therapeutics Inc – Monotherapy Products in Pipeline, 2011
Lorus Therapeutics Inc – Combination Treatment Modalities in Pipeline, 2011
Lorus Therapeutics Inc – Pipeline By Therapeutic Class, 2011
Lorus Therapeutics Inc - Pipeline By Target, 2011
Lorus Therapeutics Inc – Pipeline By Route of Administration, 2011
Lorus Therapeutics Inc – Pipeline By Molecule Type, 2011
Table of Content
List of Tables
List of Figures
Lorus Therapeutics Inc Snapshot
Lorus Therapeutics Inc Overview
Key Information
Key Facts
Lorus Therapeutics Inc – Research and Development Overview
Key Therapeutic Areas
Lorus Therapeutics Inc – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Lorus Therapeutics Inc – Pipeline Products Glance
Lorus Therapeutics Inc Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Lorus Therapeutics Inc–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Lorus Therapeutics Inc – Drug Profiles
GTI 2040 + Cytarabine
Product Description
Mechanism of Action
R&D Progress
LOR-2040
Product Description
Mechanism of Action
R&D Progress
LOR-2040 + Cytarabine
Product Description
Mechanism of Action
R&D Progress
Virulizin
Product Description
Mechanism of Action
R&D Progress
LOR-253
Product Description
Mechanism of Action
R&D Progress
IL-17E
Product Description
Mechanism of Action
R&D Progress
LOR-1284
Product Description
Mechanism of Action
R&D Progress
LOR-220
Product Description
Mechanism of Action
R&D Progress
LOR-253
Product Description
Mechanism of Action
R&D Progress
LOR-264
Product Description
Mechanism of Action
R&D Progress
LOR-500
Product Description
Mechanism of Action
R&D Progress
Lorus Therapeutics Inc – Pipeline Analysis
Lorus Therapeutics Inc – Pipeline Products by Therapeutic Class
Lorus Therapeutics Inc - Pipeline Products By Target
Lorus Therapeutics Inc – Pipeline Products by Route of Administration
Lorus Therapeutics Inc – Pipeline Products by Molecule Type
Lorus Therapeutics Inc – Recent Pipeline Updates
Lorus Therapeutics Inc - Dormant Projects
Lorus Therapeutics Inc - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Virulizin + Gemcitabine
Lorus Therapeutics Inc – Company Statement
Lorus Therapeutics Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Financial Deals Landscape
Lorus Therapeutics Inc, Deals Volume Summary, 2004 to YTD 2011
Lorus Therapeutics Inc, Deals Summary By Region, 2004 to YTD 2011
Lorus Therapeutics Inc, Deals Summary, 2004 to YTD 2011
Lorus Therapeutics Inc Detailed Deal Summary
Equity Offering
Lorus Therapeutics Completes Private Placement Of $2 Million
Lorus Therapeutics Completes Rights Offering Of $3.63 Million
Lorus Therapeutics Completes Private Placement Of $1.6 Million
Lorus Therapeutics Completes Private Placement Of $9.22 Million
Debt Offering
Lorus Therapeutics Completes Private Placement Of Convertible Debentures For $11.96 Million
Lorus Therapeutics Extends Co-Operative Research Agreement With NCI
Lorus Therapeutics Enters Into A Research Agreement With Dr. Guido Marcucci
Lorus Therapeutics Enters Into An Agreement With Sumitomo and Koken
Licensing Agreements
Lorus Therapeutics Extends Agreement With Zor Pharmaceuticals
Lorus Therapeutics Enters Into Licensing Agreement With Zor Pharmaceuticals
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Lorus Therapeutics Inc – Pipeline by Therapy Area and Indication, 2011
Lorus Therapeutics Inc – Pipeline by Stage of Development, 2011
Lorus Therapeutics Inc – Monotherapy Products in Pipeline, 2011
Lorus Therapeutics Inc – Combination Treatment Modalities in Pipeline, 2011
Lorus Therapeutics Inc - Phase II, 2011
Lorus Therapeutics Inc - Phase I, 2011
Lorus Therapeutics Inc - Pipeline By Therapeutic Class, 2011
Lorus Therapeutics Inc - Pipeline By Target, 2011
Lorus Therapeutics Inc – Pipeline By Route of Administration, 2011
Lorus Therapeutics Inc – Pipeline By Molecule Type, 2011
Lorus Therapeutics Inc – Recent Pipeline Updates, 2011
Lorus Therapeutics Inc - Dormant Developmental Projects, 2010
Lorus Therapeutics Inc - Discontinued Pipeline Products, 2010
Lorus Therapeutics Inc, Subsidiaries
Lorus Therapeutics Inc, Deals Summary, 2004 to YTD 2011
Lorus Therapeutics Inc, Deals Summary by Region, 2004 to YTD 2011
Lorus Therapeutics Inc, Deals Summary, 2004 to YTD 2011
LIST OF FIGURES
Lorus Therapeutics Inc – Pipeline by Therapy Area and Indication, 2011
Lorus Therapeutics Inc – Pipeline by Stage of Development, 2011
Lorus Therapeutics Inc – Monotherapy Products in Pipeline, 2011
Lorus Therapeutics Inc – Combination Treatment Modalities in Pipeline, 2011
Lorus Therapeutics Inc – Pipeline By Therapeutic Class, 2011
Lorus Therapeutics Inc - Pipeline By Target, 2011
Lorus Therapeutics Inc – Pipeline By Route of Administration, 2011
Lorus Therapeutics Inc – Pipeline By Molecule Type, 2011
